Pharmacy Drugs
Recent Posts
- Democrats Push Medical Device Liability Bill
- FDA Investigates Heparin Link in Two Delaware Deaths
- Conflict Of Interest Reported In 29 Percent Of Cancer Studies
- Interim Results Of Abbott’s PROGRESS Study Show Rapid Viral Decline In Dual-Therapy Regimen Of Kaletra(R) (lopinavir/ritonavir) And Raltegravir
- Survival For Prostate Cancer Patients Younger Than 50 Improved By Surgery
Random Posts
- Lantheus Medical Imaging, Inc. Initiates Phase 1 Study Evaluating Safety And Dosimetry Of Novel Heart Failure Imaging Agent
- Multidisciplinary Cancer Congress
- NACDS, NCPA Endorse Rep. Mike Ross' Medication Therapy Management Legislation
- Questioning The Credibility Of Some Published Clinical Trials
- Overrides Alleged on Quality Control Alarms at Generic Drug Plant
- Secret Plans To Criminalize Generic Medicines Could Hurt Poor Countries And People
- Research Considers Lean Mass Better For Developing Bones
- Survival For Prostate Cancer Patients Younger Than 50 Improved By Surgery
- Cardiologist Urges People To Get Informed About Angioplasty
- New Tests For Identifying Potentially Deadly Adulterants In Pharmaceutical Ingredients
FDA Accepts Arno Therapeutics’ IND For AR-12 A PDK1 Inhibitor That Blocks The PI3K/Akt Pathway
Posted by: admin in Pharmacy Drugs on November 23rd, 2009
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, announced that the U.S.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.